指南与共识血栓与止血

美国血液学会关于COVID-19患者血栓预防抗凝使用的动态指南:2022年3月更新——危重症患者抗凝使用

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients.
指南 / 共识 · Blood Adv · 2022-01-01

美国血液学会(ASH)基于GRADE方法制定动态指南,本次更新针对COVID-19相关危重症且无疑似或确诊静脉血栓栓塞症(VTE)的患者,新增一项有条件推荐:使用预防强度而非治疗强度抗凝。该推荐基于极低质量证据,强调需个体化评估血栓与出血风险,并呼吁开展高质量随机对照试验。

要点

  • 对COVID-19相关危重症且无疑似或确诊VTE的患者,有条件推荐预防强度优于治疗强度抗凝。
  • 推荐强调个体化评估血栓风险和出血风险。
  • 该推荐基于极低质量证据,需高质量随机对照试验比较不同抗凝强度。

核心结论

  • 对COVID-19相关危重症且无疑似或确诊VTE的患者,有条件推荐使用预防强度而非治疗强度抗凝。
  • 该有条件推荐基于极低质量证据,强调需开展高质量随机对照试验比较不同抗凝强度。

研究设计与样本

  • ASH组建多学科指南小组(包括3名患者代表),采用利益冲突最小化策略。
  • 麦克马斯特大学GRADE中心支持指南制定,包括系统证据评价(截至2022年1月)。
  • 小组按对临床医生和患者的重要性优先排序临床问题和结局,采用GRADE方法评估证据并形成推荐,推荐经公开征求意见。
  • 本次为2021年2月和2021年5月发布的动态指南更新。

主要发现

  • 小组新增1项推荐:对COVID-19相关危重症且无疑似或确诊VTE的患者,有条件推荐预防强度优于治疗强度抗凝。
  • 小组强调需个体化评估血栓风险和出血风险。
  • 该有条件推荐基于极低质量证据。

关键数值与推荐

  • 有条件推荐:对COVID-19相关危重症且无疑似或确诊VTE的患者,预防强度抗凝优于治疗强度抗凝。
  • 推荐基于极低质量证据。

临床怎么用

  • 对COVID-19相关危重症且无疑似或确诊VTE的患者,有条件推荐使用预防强度而非治疗强度抗凝。
  • 强调个体化评估血栓风险和出血风险。

局限性

  • 该有条件推荐基于极低质量证据。
  • 结论强调需开展额外的高质量随机对照试验比较不同抗凝强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE). OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for patients with COVID-19. METHODS: ASH formed a multidisciplinary guideline panel, including 3 patient representatives, and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing systematic evidence reviews (up to January 2022). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 and May 2021 as part of the living phase of these guidelines. RESULTS: The panel made 1 additional recommendation: a conditional recommendation for the use of prophylactic-intensity over therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of thrombotic and bleeding risk. CONCLUSIONS: This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation for patients with COVID-19-related critical illness.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cuker A, Tseng EK, Schünemann HJ, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Adv. 2022. PMID: 35748885. doi:10.1182/bloodadvances.2022007940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。